** Shares of telehealth company Mangoceuticals , also known as MangoRx, rise 2.1% to $3.94 premarket
** Company says it has initiated a review process to evaluate potential strategic alternatives, including but not limited to potential mergers, acquisitions, divestitures and other transactions
** MGRX has not established a timeline for completion of the review process
** Earlier this week, Eli Lilly sued three medical spas and online vendors, including MangoRx, for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss drug Zepbound
** The lawsuit came after MangoRx launched its own brand called "Trim" — a compounded, oral dissolvable tirzepatide tablet
** Up to last close, stock down 41.5% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。